Boston Scientific's Reports on Major Adverse Events of TAXUS Stent Study in Diabetic Patients

摘要

Boston Scientific Corporation has welcomed the results of an independent study demonstrating that Boston Scientific's TAXUS~(TM) paclitaxel-eluting stent (PES). The study exhibited a lower re-intervention rate and equal or iower instances of death orheart attack than the Cypher~(TM) sirolimus-eluting stent (SES) and bare-metal stents (BMS). The study, conducted at the Thoraxcenter, Erasmus University Medical Center in Rotterdam, The Netherlands, compared two-year ciinical outcomes for 708 consecutive diabetic patients treated from April 2002 to April 2004 with either aTAXUS stent (n = 250) or Cypher stent (n = 206) as part of the Research. And a group of 252 consecutive diabetic patients treated with BMS prior to Aprii 2002 was retrospectively selected as a control group.The results showed favorable rates of reintervention for the TAXUS stent compared to the Cypher stent and BMS Target lesion revascularization (TLR) occurred in a significantly lower percentage of TAXUS stent patients (5.3%) when compared with Cypher stent (13.2%) and BMS (15.6%) patients (p = 0.0037 PES vs. SES; p = 0.0004 PES vs. BMS). Target vessel revascularization (TVR), another measure of reintervention, showed similar positive trends for the TAXUS stent, which reported a TVR rate of 9.7 % compared to 15.3% for the Cypher stent (p = 0.06) and 19.5 percent for BMS (p = 0.0034).